Development, content validation and feasibility of a decision aid tool for the treatment of women with menopausal symptoms.

Introduction: Despite research supporting menopause hormonal therapy for menopausal women, its use continues to decline in most European countries and the United States. Experts highlighted the need for global assessment tools to assist clinicians in evaluating treatment for symptomatic menopausal women, which led to the development of the Menopause Treatment Tool, with separate versions for women and healthcare professionals. Both versions of the tool focus on menopausal symptoms, risk levels and suggested actions; the women's tool is administered prior to the consultation, while the clinician tool is administered by the clinician during the clinical consultation.

Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings.

Two important studies evaluating the safety profile of oral estrogen-progestogen hormonal therapies conducted in standard clinical practice with respect to the venous system were recently published. A large prospective controlled cohort study (PRO-E2) based on the non-inferiority design has shown that the relative risk of developing venous thrombosis (VTE) in women using combined oral hormonal contraceptives (COHC) containing 17β-estradiol (1.5 mg) and nomegestrol acetate (2.

Pulmonary blastoma in a pregnant woman: a case report and brief review of the literature.

Background: Pulmonary blastoma (PB) comprises a rare heterogeneous group of lung tumours typically containing immature epithelial and mesenchymal structures that imitate the embryonic lung tissue and extremely rarely occurs during pregnancy. Although cough and haemoptysis are the most common PB symptoms, they usually indicate other serious pregnancy-related complications.

Case Presentation: The article presents the unusual case of a 22-year-old pregnant woman diagnosed with PB during pregnancy.

Position Statement by Experts of the Polish Menopause and Andropause Society on menopausal hormone therapy with an oral combination drug containing oestradiol 1 mg and progesterone 100 mg.

At a meeting held on 20 May 2021, reviewed the available literature on the use of the medicinal product Bijuva® for the relief of menopausal symptoms.